Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Last trade$7.50
Day change+$0.36 (+5.04%)
Day range$6.96 – $7.88
Volume11,299
Market cap$8M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.58M
Price / earnings
—
Price / book
0.52×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.01×
Profitability
Earnings per share
-$13.56
Return on assets
-69.41%
Return on equity
-99.33%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.37×
Quick ratio
1.37×
Cash ratio
1.19×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$27.1M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MBRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.11M
$2.1M
$2.49M
$2.41M
$2.15M
$2.09M
$2.48M
$2.16M
Research and development
$4.49M
$5.45M
$5.38M
$5.12M
$3.74M
$3.6M
$3.44M
$4.46M
Total operating expenses
$6.61M
$7.56M
$7.87M
$7.53M
$5.91M
$5.72M
$5.94M
$6.64M
Operating income
-$6.61M
-$7.56M
-$7.87M
-$7.53M
-$5.91M
-$5.72M
-$5.94M
-$6.64M
Interest expense
$0
-$78K
$0
$0
$0
$26K
$0
$0
Income before taxes
-$6.49M
-$7.64M
-$12.85M
$15.45M
-$25.4M
-$17.81M
-$5.9M
-$6.58M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$6.49M
-$7.64M
-$12.85M
$15.45M
-$25.4M
-$17.81M
-$5.9M
-$6.58M
Net income attributable to common shareholders
-$7.27M
-$7.96M
-$14.61M
$15.45M
-$25.4M
-$17.81M
-$5.9M
-$6.58M
EBITDA
-$6.6M
-$7.55M
-$7.87M
-$7.52M
-$5.88M
-$5.69M
-$5.91M
-$6.61M
Basic earnings per share
-$9.59
-$28.00
-$70.80
$137.24
-$340.43
-$573.60
-$316.00
-$652.10
Diluted earnings per share
-$9.59
-$28.00
-$70.80
$137.24
-$340.43
-$573.60
-$316.00
-$652.10
Recent news
Company coverage with links to the original publishers.
Moleculin Biotech announced that data from its pivotal Phase 2/3 MIRACLE trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) has been accepted for presentation at the 2026 ASH Annual Meeting. First interim results from 45 randomized patients showed complete remission rates of 43% and 36% in the two Annamycin treatment arms compared to 12% in the placebo arm, with no observed cardiotoxicity. The independent Data Monitoring Committee recommended continuing the study without modification, with a comprehensive data readout expected in Q1 2027.
Moleculin Biotech announced the publication of a peer-reviewed cardiac safety analysis of Annamycin in Frontiers in Cardiovascular Medicine. A pooled analysis of five clinical trials involving 90 patients found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits, with independent evaluation by Cleveland Clinic supporting continued clinical development.
The global cell therapy manufacturing market is projected to reach $14 billion by 2035, driven by over 1,000 active clinical candidates. FDA regulatory flexibility is accelerating timelines for cell and gene therapy approvals. Several biotech companies are advancing scalable manufacturing capabilities and clinical programs: Avaí Bio is producing Master Cell Banks for α-Klotho therapy; ImmunityBio validated scalable NK cell manufacturing; Fate Therapeutics achieved outpatient CAR T-cell therapy for autoimmune diseases; Fractyl Health completed pivotal trial randomization for GLP-1 weight maintenance; and Moleculin Biotech enrolled its 45th subject in a Phase 2B/3 AML trial.
Moleculin Biotech (MBRX) released a CEO Corner segment discussing progress on its pivotal Phase 3 MIRACLE Study evaluating Annamycin combined with cytarabine for relapsed or refractory acute myeloid leukemia. The adaptive trial includes an initial cohort of 45 patients with interim unblinding planned after treatment completion. Enrollment and dosing are progressing as planned, building on encouraging results from the earlier MB-106 Study.
Over 100 pharmaceutical companies are actively developing 150+ pipeline drugs for Acute Myeloid Leukemia (AML), with approximately 10 drugs in late-stage development and 50+ in mid and early stages, focusing on targeted therapies and personalized treatment approaches.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.